Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells

Patent metadata

Field	Value
Publication number	US-9333256-B2
Application number	US-201414464447-A
Country	US
Kind code	B2
Filing date	Aug 20, 2014
Priority date	Jan 30, 2002
Publication date	May 10, 2016
Grant date	May 10, 2016

Abstract

The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.

First claim

We claim:

1. A method for treating a subject having cancer, the method comprising administering a TIM-3 (T cell Immunoglobulin and Mucin domain containing molecule-3) binding molecule in an amount effective to promote T-cell trafficking to a target tissue, wherein the TIM-3 binding molecule is a TIM-3 antibody or antigen-binding fragment thereof, in combination with a chemotherapeutic agent, thereby treating the cancer.

2. The method of claim 1 , wherein the chemotherapeutic agent is directly toxic to cancer cells.

3. The method of claim 2 , wherein the chemotherapeutic agent is an alkylating/alkaloid agent.

4. The method of claim 3 , wherein the alkylating/alkaloid agent comprises a nitrogen mustard.

5. The method of claim 4 , wherein the nitrogen mustard is selected from the group consisting of: mechlorethamin HCl, chlorambucil, and ifosfamide.

6. The method of claim 3 , wherein the alkylating/alkaloid agent is selected from the group consisting of: cisplatin, carboplatin, carmustine, lomustine, streptozocin, busulfan, procarbozine, and temozolomide.

7. The method of claim 2 , wherein the chemotherapeutic agent is selected from the group consisting of: busulfan, capecitabine, carboplatin, carmustaine, chlorambucil, cisplatin, cladribine, cytarabine HCl, daunorubicine HCl, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil (5-FU), gemcitabine, ifosfamide, irinotecan, lomustine (CCNU), mechlorethamine HCl (nitrogen mustard), mercaptopurine, mitoxantrone, mitoxantrone HCl, paclitaxel, pentostatin, plicamycin, semustine, streptozocin, taxane analog, temozolomide, teniposide (VM-26), thioguanine, vinblastine sulfate, and vindesine sulfate.

8. The method of claim 1 , wherein the TIM-3 antibody or antigen-binding fragment thereof binds to an extracellular region of TIM-3.

9. The method of claim 1 , wherein the TIM-3 antibody or antigen-binding fragment thereof is administered directly to the target tissue.

10. The method of claim 1 , wherein the TIM-3 antibody or antigen-binding fragment thereof is administered intravenously.

Assignees

• Brigham & Womens Hospital
• Dana Farber Cancer Inst Inc
• Dana Farber Cancer Inst Inc

Inventors

• Kuchroo Vijay K
• Monney Laurent
• Gaglia Jason L
• Greenfield Edward A
• Freeman Gordon J
• Waldner Hanspeter

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title